ATE345811T1 - Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen - Google Patents
Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungenInfo
- Publication number
- ATE345811T1 ATE345811T1 AT00908254T AT00908254T ATE345811T1 AT E345811 T1 ATE345811 T1 AT E345811T1 AT 00908254 T AT00908254 T AT 00908254T AT 00908254 T AT00908254 T AT 00908254T AT E345811 T1 ATE345811 T1 AT E345811T1
- Authority
- AT
- Austria
- Prior art keywords
- neurotrophin
- methods
- disorders
- hypomobility
- treat gastrointestinal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/232,171 US6656474B1 (en) | 1999-01-15 | 1999-01-15 | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE345811T1 true ATE345811T1 (de) | 2006-12-15 |
Family
ID=22872143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00908254T ATE345811T1 (de) | 1999-01-15 | 2000-01-11 | Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen |
Country Status (13)
Country | Link |
---|---|
US (1) | US6656474B1 (de) |
EP (1) | EP1146899B1 (de) |
JP (1) | JP4489303B2 (de) |
AT (1) | ATE345811T1 (de) |
AU (1) | AU775860B2 (de) |
CA (1) | CA2360252C (de) |
DE (1) | DE60031951D1 (de) |
IL (2) | IL144315A0 (de) |
NO (1) | NO329488B1 (de) |
NZ (1) | NZ512968A (de) |
TR (2) | TR200201875T2 (de) |
WO (1) | WO2000041719A1 (de) |
ZA (1) | ZA200105799B (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
AU7142201A (en) * | 2000-06-22 | 2002-01-02 | Genentech Inc | Agonist anti-trk-c monoclonal antibodies |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
EP1620127A4 (de) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | Verfahren zur behandlung von taxol-induzierten darmstörungen |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
PL3013353T3 (pl) | 2013-06-26 | 2021-09-20 | Xigen Inflammation Ltd. | Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US5962404A (en) * | 1989-08-28 | 1999-10-05 | Yeda Research & Development Co., Ltd. | Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor |
US6174701B1 (en) * | 1989-12-12 | 2001-01-16 | Genentech, Inc. | Neuronal factor |
WO1994006455A1 (en) * | 1992-09-14 | 1994-03-31 | Regeneron Pharmaceuticals, Inc. | Method of producing analgesia using neurotrophins |
US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
DE69535221T2 (de) | 1994-04-25 | 2007-09-13 | Genentech, Inc., South San Francisco | Cardiotrophin und verwendung davon |
US5759775A (en) * | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US6211142B1 (en) | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
US5616724A (en) * | 1996-02-21 | 1997-04-01 | Cephalon, Inc. | Fused pyrrolo[2,3-c]carbazole-6-ones |
JP3540912B2 (ja) * | 1997-03-28 | 2004-07-07 | 京セラ株式会社 | 釣糸用ガイド部材 |
WO1998049308A1 (en) | 1997-04-25 | 1998-11-05 | Genentech, Inc. | Ngf variants |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
-
1999
- 1999-01-15 US US09/232,171 patent/US6656474B1/en not_active Expired - Lifetime
-
2000
- 2000-01-11 JP JP2000593329A patent/JP4489303B2/ja not_active Expired - Lifetime
- 2000-01-11 NZ NZ512968A patent/NZ512968A/en not_active IP Right Cessation
- 2000-01-11 DE DE60031951T patent/DE60031951D1/de not_active Expired - Lifetime
- 2000-01-11 CA CA2360252A patent/CA2360252C/en not_active Expired - Lifetime
- 2000-01-11 EP EP00908254A patent/EP1146899B1/de not_active Expired - Lifetime
- 2000-01-11 WO PCT/US2000/000682 patent/WO2000041719A1/en active IP Right Grant
- 2000-01-11 AU AU29636/00A patent/AU775860B2/en not_active Expired
- 2000-01-11 TR TR2002/01875T patent/TR200201875T2/xx unknown
- 2000-01-11 TR TR2001/02767T patent/TR200102767T2/xx unknown
- 2000-01-11 AT AT00908254T patent/ATE345811T1/de not_active IP Right Cessation
- 2000-01-11 IL IL14431500A patent/IL144315A0/xx active IP Right Grant
-
2001
- 2001-07-13 ZA ZA200105799A patent/ZA200105799B/en unknown
- 2001-07-13 IL IL144315A patent/IL144315A/en not_active IP Right Cessation
- 2001-07-13 NO NO20013493A patent/NO329488B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200105799B (en) | 2002-01-24 |
US6656474B1 (en) | 2003-12-02 |
CA2360252A1 (en) | 2000-07-20 |
JP4489303B2 (ja) | 2010-06-23 |
TR200201875T2 (tr) | 2002-09-23 |
EP1146899B1 (de) | 2006-11-22 |
NO329488B1 (no) | 2010-10-25 |
JP2002534479A (ja) | 2002-10-15 |
NO20013493D0 (no) | 2001-07-13 |
EP1146899A4 (de) | 2003-03-05 |
IL144315A (en) | 2008-08-07 |
NO20013493L (no) | 2001-09-17 |
EP1146899A1 (de) | 2001-10-24 |
CA2360252C (en) | 2010-11-02 |
AU2963600A (en) | 2000-08-01 |
TR200102767T2 (tr) | 2002-04-22 |
AU775860B2 (en) | 2004-08-19 |
IL144315A0 (en) | 2002-05-23 |
WO2000041719A9 (en) | 2001-08-30 |
NZ512968A (en) | 2003-09-26 |
WO2000041719A1 (en) | 2000-07-20 |
DE60031951D1 (de) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE345811T1 (de) | Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen | |
DE60015070D1 (de) | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache | |
DE60120667D1 (de) | Methoden und mittel zur behandlung von bandscheibenverschleiss | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE69813898D1 (de) | Substituierte porphyrinen | |
DE60233955D1 (de) | Spezifische bindungsmittel von human angiopoietin-2 | |
DE69931377D1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
ATE215822T1 (de) | Verwendung von rapamycin zur behandlung von anämie | |
ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
DE69929464D1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
ATE374619T1 (de) | Verwendung von neurofilamentproteinen zur behandlung von tumoren | |
ATE209909T1 (de) | Verwendung von tachykinin-antagonisten zur behandlung von erbrechen | |
DE50111057D1 (de) | Hochverzweigte polymere zur antiknitterausrüstung von cellulosehaltigen textilien | |
DE69721756D1 (de) | Paroxetine zur behandlung von depression | |
DE69915690D1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
ATE476987T1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
ATE409732T1 (de) | Methoden zur vorbehandlung von schuhen | |
ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
DE69806062D1 (de) | Kombinationstherapie zur behandlung von aids | |
SE0003126D0 (sv) | Method of treatment | |
ATE258064T1 (de) | Verwendung von antileukoprotease zur behandlung von endometriose | |
DE50210718D1 (de) | Verfahren zur behandlung von schlamm | |
DE60213230D1 (de) | Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit | |
ATE371445T1 (de) | Verfahren zur prävention und/oder behandlung von asthma mit parabromophenacyl bromide (pbpb) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |